EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk

Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, John W Eikelboom, Arend Mosterd iD, Aernoud T L Fiolet, Jan G P Tijssen, Peter L Thompson, Dominique P V de Kleijn, Sotirios Tsimikas, Jan H Cornel iD, Calvin Yeang und 1 weitere

European Journal of Preventive Cardiology · 14.07.2025 · 32 (9) · 758-765

DOI: 10.1093/eurjpc/zwae355 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Preventive Cardiology, online erschienen am 30.10.2024. Verfasst von Niekbachsh Mohammadnia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Colchicine, Lipoprotein(a), Phospholipids, Cardiovascular Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Health Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The low-dose colchicine 2 (LoDoCo2) trial showed that colchicine reduced the risk of cardiovascular events occurring on standard therapies in patients with chronic coronary syndrome (CCS). We explored the effects of colchicine on Lp(a)- and oxidized lipoprotein-associated risk in a LoDoCo2 biomarker subpopulation. Methods and results Lipoprotein(a) and OxPLs on apolipoprotein(a) [OxPL-apo(a)] and apolipoprotein B-100 (OxPL-apoB) levels were determined in the biomarker population of the LoDoCo2 trial (n = 1777). The Cox regression analysis was used to compare the risk of the primary endpoint, consisting of myocardial infarction, ischaemic stroke, or ischaemia-driven revascularization by biomarker levels. Interactions between treatment, Lp(a), and OxPL levels were evaluated. Lipoprotein(a), OxPL-apo(a), and OxPL-apoB levels were similar between the colchicine and placebo groups. Consistent risk reduction by colchicine was observed in those with Lp(a) < 125 nmol/L and ≥125 nmol/L and the highest OxPL-apo(a) tertile compared with the lowest (Pinteraction = 0.92 and 0.66). The absolute risk reduction for those with Lp(a) ≥ 125 nmol/L appeared higher compared with those with Lp(a) < 125 nmol/L (4.4% vs. 2.4%). A treatment interaction for colchicine was found in those with the highest OxPL-apoB tertile vs. the lowest (Pinteraction = 0.04).

Conclusion

In patients with CCS, colchicine reduces cardiovascular disease risk in those with and without elevated Lp(a) but absolute benefits appeared higher in those with Lp(a) ≥ 125 nmol/L. Patients with higher levels of OxPL-apoB experienced greater benefit of colchicine, suggesting that colchicine may be more effective in subjects with heightened oxidation-driven inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColchicineLipoprotein(a)PhospholipidsCardiovascular DiseasesHumansMaleBiomarkersFemaleMiddle AgedTreatment OutcomeAgedOxidation-ReductionApolipoprotein B-100Risk AssessmentDouble-Blind MethodHeart Disease Risk FactorsRisk FactorsTime Factors

Stichwörter der Autor:innen

ColchicineInflammationLipoprotein(a)LipoproteinsOxidized phospholipidsSecondary prevention

Substanzen

ColchicineLipoprotein(a)BiomarkersPhospholipidsApolipoprotein B-100

Autor:innen und Institutionen

  • Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
  • Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Dutch Network for Cardiovascular Research (WCN), Utrecht, The Netherlands.
  • Department of Cardiology, Meander Medical Center, Amersfoort, The Netherlands.
  • Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Arend Mosterd, Jan H Cornel

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Health Medical Research Council
  • National Institutes of Health

Zitieren

APA

Mohammadnia, N., van Broekhoven, A., Bax, W. A., Eikelboom, J. W., Mosterd, A., Fiolet, A. T. L., Tijssen, J. G. P., Thompson, P. L., de Kleijn, D. P. V., Tsimikas, S., Cornel, J. H., Yeang, C., & El Messaoudi, S. (2025). The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk. European Journal of Preventive Cardiology, 32(9), 758-765. https://doi.org/10.1093/eurjpc/zwae355

Vancouver

Mohammadnia N, van Broekhoven A, Bax WA, Eikelboom JW, Mosterd A, Fiolet ATL, et al. The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk. European Journal of Preventive Cardiology. 2025;32(9):758-765. doi:10.1093/eurjpc/zwae355

BibTeX
@article{Mohammadnia2025,
  author = {Mohammadnia, Niekbachsh and van Broekhoven, Amber and Bax, Willem A and Eikelboom, John W and Mosterd, Arend and Fiolet, Aernoud T L and Tijssen, Jan G P and Thompson, Peter L and de Kleijn, Dominique P V and Tsimikas, Sotirios and Cornel, Jan H and Yeang, Calvin and El Messaoudi, Saloua},
  title = {The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk},
  journal = {European Journal of Preventive Cardiology},
  year = {2025},
  volume = {32},
  number = {9},
  pages = {758--765},
  doi = {10.1093/eurjpc/zwae355}
}
Kostenlos starten →